Zacks Investment Research
17 Nov 2026, 17:51 UTC · 8h ago
Is NPCE Worth Buying Now as Growth Potential Meets Execution Risk?
Impact · against what's priced in
The outlook for NPCE is negative as stagnant Q3 2026 revenue growth (1.4% YoY) confirms that expanding physician interest is not translating into procedure volume. While the stock trades at a significant discount to its sub-industry multiple, this valuation floor is offset by persistent losses and commercial disruption.
- NPCE−0.40
No priced-in read yet
- In context
Revenues grew only 1.4% year-over-year in Q3 2026, suggesting a failure to convert prescriber growth into implants. Despite a low 2.29X forward sales multiple, ongoing losses and commercial disruption weigh on the setup.
Read from the article alone

Top 2 movers · tap to explore




